Download PDF
Viszeralchirurgie 2007; 42(2): 89-93
DOI: 10.1055/s-2007-960664
Originalarbeit

© Georg Thieme Verlag Stuttgart · New York

Chirurgie des Pankreaskarzinoms - Qualitätssicherung

Surgery of Pancreatic Cancer - Quality ManagementT. Schmidt1 , M. Koch1 , I. Esposito2 , P. Schirmacher2 , M. W. Büchler1 , J. Weitz1
  • 1Abteilung für Allgemein-, Viszeral- und Unfallchirurgie, Chirurgische Universitätsklinik Heidelberg
  • 2Pathologisches Institut der Universität Heidelberg
Further Information

Publication History

Publication Date:
22 May 2007 (online)

    Permissions and Reprints

Zusammenfassung

Patienten mit einem Pankreaskarzinom haben häufig eine schlechte Prognose. Die Frage einer Qualitätssicherung der onkologischen Behandlung dieser Erkrankung scheint daher hinter der aggressiven Tumorbiologie auf den ersten Blick zurückzustehen. Interessanterweise belegen zahlreiche Studien und Daten, dass die Qualität der onkologischen Therapie beim Pankreaskarzinom stark von der Erfahrung und dem Patientenaufkommen der behandelnden Klinik abhängen. Dabei spielen nicht nur der Operateur sondern auch die Erfahrung des Pathologen, Onkologen, Radiologen und des gesamten multidisziplinären Behandlungsteams eine wichtige Rolle. Die Behandlung des Pankreaskarzinoms sollte nur an erfahrenen und spezialisierten Zentren erfolgen, um die Qualität der onkologischen Versorgung bei dieser Erkrankung sicherzustellen und damit auch die Langzeitprognose der Patienten zu verbessern.

Abstract

Patients with pancreatic cancer usually have a poor prognosis. Therefore, it remains questionable whether quality control of the oncological treatment of pancreatic cancer patients is of any importance compared to the aggressive tumor biology. Interestingly, numerous studies and data revealed a clear relationship between hospital volume and outcome for patients with pancreatic cancer. Beside surgeon's experience, the experience and quality of the treating pathologist, oncologist, radiologist and the whole multidisciplinary team also seems to play an important role. Pancreatic cancer should only be treated in experienced and specialised centers in order to provide adequate oncological therapy and to improve long term prognosis of the patients.

Schlüsselwörter

Qualitätssicherung - Onkologie - Chirurgie - Pankreaskarzinom

Key words

Quality control - surgical oncology - pancreatic cancer

Literatur

  • 1 Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun M J. Cancer statistics, 2006.  CA Cancer J Clin. 2006;  56 106-130
    Google Scholar
  • 2 Chua Y J, Cunningham D. Adjuvant treatment for resectable pancreatic cancer.  J Clin Oncol. 2005;  23 4532-4537
    CrossrefPubMedGoogle Scholar
  • 3 Neoptolemos J P, Stocken D D, Dunn J A. et al . Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and / or chemotherapy in the ESPAC-1 randomized controlled trial.  Ann Surg. 2001;  234 758-768
    CrossrefPubMedGoogle Scholar
  • 4 Neoptolemos J P, Dunn J A, Stocken D D. et al . Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.  Lancet. 2001;  358 1576-1585
    CrossrefPubMedGoogle Scholar
  • 5 Albores-Saavedra J, Heffess C, Hruban R H, Klimstra D, Longnecker D. Recommendations for the reporting of pancreatic specimens containing malignant tumors. The Association of Directors of Anatomic and Surgical Pathology.  Am J Clin Pathol. 1999;  111 304-307
    PubMedGoogle Scholar
  • 6 Lüttges J, Zamboni G, Klöppel G. Recommendation for the examination of pancreaticoduodenectomy specimens removed from patients with carcinoma of the exocrine pancreas.  Dig Surg. 1999;  16 291-296
    CrossrefPubMedGoogle Scholar
  • 7 Lüttges J, Vogel I, Menke M. et al . The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas.  Virch Arch. 1998;  433 237-242
    PubMedGoogle Scholar
  • 8 Verbeke C S, Leitch D, Menon K V, McMahon M J, Guillou P J, Anthoney A. Redefining the R1 resection in pancreatic cancer.  Br J Surg. 2006;  93 1232-1237
    CrossrefPubMedGoogle Scholar
  • 9 Neoptolemos J P, Stocken D D, Friess H. et al . A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.  N Engl J Med. 2004;  350 1200-1210
    CrossrefPubMedGoogle Scholar
  • 10 Kuhlmann K, de Castro S, van Heek T. et al . Microscopically incomplete resection offers acceptable palliation in pancreatic cancer.  Surgery. 2006;  139 188-196
    CrossrefPubMedGoogle Scholar
  • 11 Chaudry I H, Campbell F. An audit of pathology lymph node dissection techniques in pylorus preserving Kausch-Whipple pancreatoduodenectomy specimens.  J Clin Pathol. 2001;  54 758-761
    PubMedGoogle Scholar
  • 12 Lüttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Klöppel G. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation.  J Pathol. 2000;  191 154-161
    PubMedGoogle Scholar
  • 13 Oettle H, Post S, Neuhaus P. et al . Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer.  JAMA. 2007;  297 267-277
    CrossrefPubMedGoogle Scholar
  • 14 Riall T S, Nealon W H, Goodwin J S. et al . Pancreatic cancer in the general population: improvements in survival over the last decade.  J Gastrointest Surg. 2006;  10 1212-1224
    CrossrefPubMedGoogle Scholar
  • 15 Sohn T A, Yeo C J, Cameron J L. et al . Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators.  J Gastrointest Surg. 2000;  4 567-579
    CrossrefPubMedGoogle Scholar
  • 16 Geer R J, Brennan M F. Prognostic indicators for survival after resection of pancreatic adenocarcinoma.  Am J Surg. 1993;  165 68-72
    CrossrefPubMedGoogle Scholar
  • 17 Buchler M W, Friess H, Wagner M, Kulli C, Wagener V, Z'Graggen K. Pancreatic fistula after pancreatic head resection.  Br J Surg. 2000;  87 883-889
    CrossrefPubMedGoogle Scholar
  • 18 Riall T S, Cameron J L, Lillemoe K D. et al . Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma - part 3: update on 5-year survival.  J Gastrointest Surg. 2005;  9 1191-1204 ,  discussion 1204-1206
    CrossrefPubMedGoogle Scholar
  • 19 Winter J M, Cameron J L, Campbell K A. et al . 1 423 Pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.  J Gastrointest Surg. 2006;  10 1199-1211
    CrossrefPubMedGoogle Scholar
  • 20 Friess H, Kleeff J, Fischer L, Muller M, Buchler M W. Surgical standard therapy for cancer of the pancreas.  Chirurg. 2003;  74 183-190
    CrossrefPubMedGoogle Scholar
  • 21 Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos J P. Current standards of surgery for pancreatic cancer.  Br J Surg.. 2004;  91 1410-1427
    CrossrefPubMedGoogle Scholar
  • 22 Wray C J, Ahmad S A, Matthews J B, Lowy A M. Surgery for pancreatic cancer: recent controversies and current practice.  Gastroenterology. 2005;  128 1626-1641
    CrossrefPubMedGoogle Scholar
  • 23 Kausch W. Das Karzinom der Papilla duodeni und seine radikale Entfernung.  Beitr Klin Chir. 1912;  78 439
    PubMedGoogle Scholar
  • 24 Whipple A O, Parsons W B, Mullins C R. Treatment of carcinoma of the ampulla of Vater.  Ann Surg. 1935;  102 763
    CrossrefPubMedGoogle Scholar
  • 25 Traverso L W, Longmire Jr  W P. Preservation of the pylorus in pancreaticoduodenectomy.  Surg Gynecol Obstet.. 1978;  146 959-962
    PubMedGoogle Scholar
  • 26 Traverso L W, Longmire Jr  W P. Preservation of the pylorus in pancreaticoduodenectomy a follow-up evaluation.  Ann Surg. 1980;  192 306-310
    PubMedGoogle Scholar
  • 27 Seiler C A, Wagner M, Bachmann T. et al . Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results.  Br J Surg. 2005;  92 547-556
    CrossrefPubMedGoogle Scholar
  • 28 Tran K T, Smeenk H G, van Eijck C H. et al . Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors.  Ann Surg. 2004;  240 738-745
    CrossrefPubMedGoogle Scholar
  • 29 Diener M K, Knaebel H P, Heukaufer C, Antes G, Büchler M W, Seiler C M. A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma.  Ann Surg. 2007;  245 187-200
    CrossrefPubMedGoogle Scholar
  • 30 Knaebel H P, Diener M K, Wente M N, Büchler M W, Seiler C M. Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy.  Br J Surg. 2005;  92 539-546
    CrossrefPubMedGoogle Scholar
  • 31 Bramhall S R, Allum W H, Jones A G, Allwood A, Cummins C, Neoptolemos J P. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study.  Br J Surg. 1995;  82 111-115
    CrossrefPubMedGoogle Scholar
  • 32 Yeo C J, Cameron J L, Sohn T A. et al . Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes.  Ann Surg. 1997;  226 248-257
    CrossrefPubMedGoogle Scholar
  • 33 Luft H S, Bunker J P, Enthoven A C. Should operations be regionalized? The empirical relation between surgical volume and mortality.  N Engl J Med.. 1979;  301 1364-1369
    CrossrefPubMedGoogle Scholar
  • 34 Birkmeyer J D, Siewers A E, Finlayson E V. et al . Hospital volume and surgical mortality in the United States.  N Engl J Med.. 2002;  346 1128-1137
    CrossrefPubMedGoogle Scholar
  • 35 Finlayson E V, Birkmeyer J D. Effects of hospital volume on life expectancy after selected cancer operations in older adults: a decision analysis.  J Am Coll Surg. 2003;  196 410-417
    CrossrefPubMedGoogle Scholar
  • 36 Birkmeyer J D, Dimick J B, Staiger D O. Operative mortality and procedure volume as predictors of subsequent hospital performance.  Ann Surg. 2006;  243 411-417
    CrossrefPubMedGoogle Scholar
  • 37 Birkmeyer J D, Stukel T A, Siewers A E, Goodney P P, Wennberg D E, Lucas F L. Surgeon volume and operative mortality in the United States.  N Engl J Med. 2003;  349 2117-2127
    CrossrefPubMedGoogle Scholar
  • 38 Weitz J, Koch M, Friess H, Büchler M W. Impact of volume and specialization for cancer surgery.  Dig Surg. 2004;  21 253-261
    PubMedGoogle Scholar
  • 39 Birkmeyer J D, Dimick J B. Potential benefits of the new Leapfrog standards: effect of process and outcome measures.  Surgery. 2004;  135 569-575
    CrossrefPubMedGoogle Scholar
  • 40 van Heek N T, Kuhlmann K F, Scholten R J. et al . Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands.  Ann Surg. 2005;  242 781-788
    CrossrefPubMedGoogle Scholar
  • 41 Wagner M, Redaelli C, Lietz M, Seiler C A, Friess H, Buchler M W. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma.  Br J Surg. 2004;  91 586-594
    CrossrefPubMedGoogle Scholar
  • 42 Pedrazzoli S, DiCarlo V, Dionigi R. et al . Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.  Ann Surg. 1998;  228 508-517
    Google Scholar
  • 43 Yeo C J, Cameron J L, Lillemoe K D. et al . Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.  Ann Surg. 2002;  236 355-366
    Google Scholar
  • 44 Bentrem D J, Brennan M F. Outcomes in oncologic surgery: does volume make a difference?.  World J Surg. 2005;  29 1210-1216
    CrossrefPubMedGoogle Scholar
  • 45 Fong Y, Gonen M, Rubin D, Radzyner M, Brennan M F. Long-term survival is superior after resection for cancer in high-volume centers.  Ann Surg. 2005;  242 540-544
    PubMedGoogle Scholar
  • 46 Leach S D, Lee J E, Charnsangavej C. et al . Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head.  Br J Surg. 1998;  85 611-617
    CrossrefPubMedGoogle Scholar
  • 47 Bachellier P, Nakano H, Oussoultzoglou P D. et al . Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?.  Am J Surg. 2001;  182 120-129
    CrossrefPubMedGoogle Scholar
  • 48 Nakagohri T, Kinoshita T, Konishi M, Inoue K, Takahashi S. Survival benefits of portal vein resection for pancreatic cancer.  Am J Surg. 2003;  186 149-153
    CrossrefPubMedGoogle Scholar
  • 49 van Geenen R C, ten Kate F J, de Wit L T, van Gulik T M, Obertop H, Gouma D J. Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy.  Surgery. 2001;  129 158-163
    PubMedGoogle Scholar

Prof. Dr. J. WeitzMSc 

Sektion Chirurgische Onkologie

Im Neuenheimer Feld 110

69120 Heidelberg

Phone: 0 62 21/56 62 50

Fax: 0 62 21/56 55 06

Email: Jürgen.Weitz@med.uni-heidelberg.de